Therapeutic potentials of Apatinib in cancer treatment: Possible mechanisms and clinical relevance.
Angiogenesis Inhibitors
/ pharmacology
Antineoplastic Agents
/ pharmacology
Apoptosis
/ drug effects
Cell Proliferation
/ drug effects
Chemotherapy, Adjuvant
Clinical Trials as Topic
Drug Resistance, Neoplasm
/ drug effects
Humans
Neoplasms
/ blood supply
Protein Kinase Inhibitors
/ therapeutic use
Pyridines
/ pharmacology
Vascular Endothelial Growth Factor Receptor-2
/ antagonists & inhibitors
Apatinib
Cancer treatment
Vascular endothelial growth factor
Vascular endothelial growth factor receptor
Journal
Life sciences
ISSN: 1879-0631
Titre abrégé: Life Sci
Pays: Netherlands
ID NLM: 0375521
Informations de publication
Date de publication:
15 Jan 2020
15 Jan 2020
Historique:
received:
10
09
2019
revised:
15
11
2019
accepted:
25
11
2019
pubmed:
2
12
2019
medline:
7
2
2020
entrez:
2
12
2019
Statut:
ppublish
Résumé
Metastasis is one of the main issues in cancer treatment and it has been documented that angiogenesis plays an important role in this process. Studies showed that vascular endothelial growth factor (VEGF) and its receptor (VEGFR) have elevated expression in tumors and are involved in tumor progression and metastasis; suggesting their potential for being a therapeutic target. In this regard, Apatinib or YN968D1, a specific inhibitor of VEGFR-2 has been suggested as a promising therapeutic agent for cancer that can prevent tumor angiogenesis and metastasis. Furthermore, this drug can sensitize resistant tumor cells to chemotherapy drugs and increase the effectiveness of conventional chemotherapy drugs. Recent studies have shown that Apatinib has beneficial implications as a post-second and third-line therapy agent in a variety of cancers. Furthermore, Apatinib has the capacity to promote the overall survival and progression-free survival of cancer patients. This review discussed about, the molecular mechanisms and clinical relevance underlying the therapeutic potential of Apatinib in cancer treatment.
Identifiants
pubmed: 31786193
pii: S0024-3205(19)31033-1
doi: 10.1016/j.lfs.2019.117106
pii:
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Antineoplastic Agents
0
Protein Kinase Inhibitors
0
Pyridines
0
apatinib
5S371K6132
KDR protein, human
EC 2.7.10.1
Vascular Endothelial Growth Factor Receptor-2
EC 2.7.10.1
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
117106Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.